Table 2.
Clinical trials involving anti-PD-1 or anti-PD-L1 antibodies
| Class | Agent | Intervention | Condition | Phase | Clinical Trial ID | Other title |
|---|---|---|---|---|---|---|
| Anti-PD-1 antibody | Pembrolizumab | Single therapy | R/R or disseminated malignant neoplasms including NHL or CHL in HIV-positive patients | I | NCT02595866 | |
| Single therapy | PD-L1-positive R/R lymphoma in pediatric patients | I/II | NCT02332668 | KEYNOTE-051 | ||
| Single therapy | CD19+ DLBCL, FL, or MCL who failed anti-CD19 CAR-T | I/II | NCT02650999 | |||
| Single therapy | R/R MF/SS | II | NCT02243579 | |||
| Single therapy | R/R PMBL | II | NCT02576990 | |||
| Single therapy | Recurrent PCNSL | II | NCT02779101 | |||
| Single therapy | R/R PTCL | II | NCT02535247 | |||
| Single therapy | In the lymphocyte recovery phase after high-dose chemotherapy and ASCT in PCM | II | NCT02331368 | |||
| Single therapy | Intermediate and high risk smoldering PCM | Not yet open | NCT02603887 | |||
| Pembrolizumab with dinaciclib | R/R CLL/SLL, PCM, or DLBCL | Ib | NCT02684617 | |||
| Pembrolizumab with AFM13 | R/R CHL | Ib | NCT02665650 | KEYNOTE-026 | ||
| G100 with or without pembrolizumab | FL or MZL | I/II | NCT02501473 | |||
| Pembrolizumab with INCB024360 | Cancers including DLBCL | I/II | NCT02178722 | |||
| Pembrolizumab with ACP-196 | Hematologic malignancies including NHL, PCM, Hodgkin lymphoma, CLL with or without Richter’s syndrome, and Waldenstrom macroglobulinemia | I/II | NCT02362035 | |||
| Pembrolizumab with pomalidomide | R/R PCM | I/II | NCT02289222 | |||
| Pembrolizumab with ubilituximab and TGR-1202 | R/R CLL/SLL | I/II | NCT02535286 | |||
| Pembrolizumab with idelalisib or ibrutinib | R/R low-grade B-cell lymphoma | II | NCT02332980 | |||
| Pembrolizumab with rituximab | Relapsed FL | II | NCT02446457 | |||
| Pembrolizumab as consolidation therapy | PCM with residual disease after treatment | II | NCT02636010 | |||
| Pembrolizumab as consolidation therapy after ASCT | R/R DLBCL or CHL | II | NCT02362997 | |||
| Pembrolizumab with sequential intranodal immunotherapy | Stage III/IV untreated or relapsed FL | II | NCT02677155 | |||
| Pembrolizumab with BV | R/R CHL | III | NCT02684292 | KEYNOTE-204 | ||
| Pembrolizumab with pomalidomide and low-dose dexamethasone | R/R PCM | III | NCT02576977 | KEYNOTE-183 | ||
| Pembrolizumab with lenalidomide and low-dose dexamethasone | Treatment naïve PCM | III | NCT02579863 | KEYNOTE-185 | ||
| Pembrolizumab with R-CHOP | Previously untreated DLBCL | Not described | NCT02541565 | |||
| Anti-PD-1 antibody | Nivolumab | Single therapy | Relapsed hematologic malignancies after allogeneic SCT | I | NCT01822509 | |
| Single therapy | Adult T-cell leukemia/lymphoma | II | NCT02631746 | |||
| Single therapy | R/R FL | II | NCT02038946 | CheckMate140 | ||
| Single therapy | R/R DLBCL patients who failed ASCT or were ineligible for ASCT | II | NCT02038933 | CheckMate139 | ||
| Single therapy or given with ipilimumab/lirilumab | R/R hematologic malignancies | I | NCT01592370 | |||
| Nivolumab with ipilimumab and BV | R/R CHL | I | NCT01896999 | |||
| Nivolumab with RRx-001 | Advanced lymphoma or solid tumors | I | NCT02518958 | PRIMETIME | ||
| Single therapy or with ipilimumab | R/R cancers including lymphoid neoplasms in young (12 months to 30 years) patients | I/II | NCT02304458 | |||
| Nivolumab with ibrutinib | SLL/CLL, FL, and DLBCL | I/II | NCT02329847 | |||
| Nivolumab with urelumab | Advanced B-cell NHLs | I/II | NCT02253992 | |||
| Nivolumab with INCB024360 | Cancers including DLBCL and CHL | I/II | NCT02327078 | ECHO-204 | ||
| Nivolumab with BV | R/R CHL after failure of frontline therapy | I/II | NCT02572167 | |||
| Nivolumab with BV | R/R NHLs (DLBCL, PTCL and MF/SS) with CD30 expression | I/II | NCT02581631 | |||
| Nivolumab with BMS-986016 | R/R B-cell lymphoma | I/II | NCT02061761 | |||
| Nivolumab with ipilimumab | Lymphoma or myeloma (in patients who are at high-rick for post-transplant recurrence after ASCT) | I/II | NCT02681302 | CPIT001 | ||
| Nivolumab with AVD | Newly diagnosed CHL | II | NCT02181738 | CheckMate205 cohort D | ||
| Nivolumab with ibrutinib | R/R or high-risk untreated CLL/SLL | II | NCT02420912 | |||
| Nivolumab with BV | Untreated CHL in older (≥60 years) patients | II | NCT02758717 | |||
| Nivolumab, pomalidomide, and dexamethasone | R/R PCM | III | NCT02726581 | CheckMate602 | ||
| Anti-PD-1 antibody | AMP-514 | AMP-514 with MEDI-551 | R/R aggressive B-cell lymphomas who have failed 1–2 prior lines of therapy | Ib/II | NCT02271945 | |
| Anti-PD-1 antibody | PF-06801591 | Single therapy | R/R CHL and other solid tumors | I | NCT02573259 | |
| Anti- PD-1 antibody | PDR001 | GWN323 with or without PDR001 | Advanced lymphoma or solid tumors | I | NCT02740270 | |
| Anti-PD-1 antibody | REGN2810 | Single therapy | Lymphoma | I | NCT02651662 | |
| Anti-PD-1 antibody | BGB-A317 | BGB-A317 with BGB-3111 | B-cell lymphoid malignancies | I | NCT02795182 | |
| Anti-PD-L1 antibody | Atezolizumab | Single therapy or with lenalidomide | R/R or post-ASCT PCM | Ib | NCT02431208 | |
| Atezolizumab with obinutuzumab | R/R FL or DLBCL | I | NCT02220842 | |||
| Atezolizumab with obinutuzumab and polatuzumab vedotin | R/R FL or DLBCL | Ib/II | NCT02729896 | |||
| Atezolizumab with obinutuzumab and lenalidomide | R/R FL | Ib/II | NCT02631577 | |||
| Atezolizumab, obinutuzumab and bendamustine or CHOP | Untreated or R/R FL or DLBCL | Ib/II | NCT02596971 | |||
| Anti-PD-L1 antibody | Durvalumab | Single therapy | R/R lymphoma, solid tumor, and CNS tumors in Pediatric (1 year to 17 years) patients | I | NCT02793466 | |
| Single therapy or with tremelimumab or AZD9150 | R/R DLBCL | Ib | NCT02549651 | |||
| Single therapy or with pomalidomide and with or without low- dose dexamethasone | R/R PCM | Ib | NCT02616640 | |||
| Durvalumab with anti-CD19 CAR-T | R/R DLBCL | I | NCT02706405 | |||
| Durvalumab with tremelimumab and ASCT | PCM | I | NCT02716805 | |||
| Durvalumab with tremelimumab and poly ICLC | Advanced cancers including cutaneous T-cell lymphoma | I/II | NCT02643303 | |||
| Durvalumab with ibrutinib | R/R FL or DLBCL | I/II | NCT02401048 | |||
| Durvalumab with lenalidomide with or without dexamethasone | Newly diagnosed PCM | I/II | NCT02685826 | |||
| Durvalumab with daratumumab | R/R PCM | I/II | NCT02807454 | FUSION MM-003 | ||
| Durvalumab, ibrutinib, rituximab, bendamustine, lenalidomide | CLL/SLL or other lymphoma | I/II | NCT02733042 | FUSION NHL 001 | ||
| Anti-PD-L1 antibody | Avelumab | Single therapy | Previously treated advanced stage CHL | I | NCT02603419 | JAVELIN HODGKINS |
| Anti-PD-L1 antibody | CA-170 | Single therapy | Advanced lymphoma or solid tumors | I | NCT02812875 |
Dinaciclib (MK-7965), a cyclin-dependent kinase inhibitor; AFM13, a bi-specific, tetravalent chimeric antibody construct against CD30 and CD16A; G100, a potent toll-like receptor-4 agonist; INCB024360 (Epacadostat), an indoleamine 2,3-dioxygenase 1 inhibitor; ACP-196 (Acalabrutinib), a more selective, irreversible Bruton’s Tyrosine kinase inhibitor; Pomalidomide, a derivative of thalidomide; Ubilituximab (TG-1101 or UTX), a novel, chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen; TGR-1202, a PI3K δ inhibitor; Idelalisib, a PI3K δ inhibitor; Ibrutinib, a Bruton’s Tyrosine kinase inhibitor; Rituximab, a monoclonal antibody against the protein CD20; ASCT, autologous stem cell transplant; BV (Brentuximab vedotin), an antibody-drug conjugate directed to the protein CD30; lenalidomide, a derivative of thalidomide; R-CHOP; combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; ipilimumab, a monoclonal antibody targeting CTLA-4; Lirilumab, an anti-KIR monoclonal antibody; RRx-001, a pan-epigenetic anticancer agent; Urelumab, an anti-CD137 monoclonal antibody; BMS-986016, an anti-LAG-3 monoclonal antibody (an immune checkpoint inhibitor); AVD, combination of doxorubicin, vinblastine and Dacarbazine; MEDI-551, an anti-19 monoclonal antibody; GWN323, an anti-GITR antibody (GITR: glucocorticoid-induced tumor necrosis factor receptor); BGB-3111, a Bruton’s Tyrosine kinase inhibitor; Obinutuzumab, a humanized anti-CD20 monoclonal antibody; Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate; Tremelimumab, an anti-CTLA-4 antibody; AZD9150, an anti-STAT3 inhibitor; CAR-T, chimeric antigen receptor T-cell therapy; Poly ICLC, a toll-like receptor-3 agonist; Daratumumab, a monoclonal anti-CD38 antibody; HIV, human immunodeficiency virus; R/R, relapsed and refractory; NHL, non-Hodgkin lymphoma; CHL, classical Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MF/SS, mycosis fungoides/Sezary syndrome; PMBL, primary mediastinal (thymic) large B-cell lymphoma; PCNSL, primary central nervous system lymphoma; PTCL, peripheral T-cell lymphoma; PCM, plasma cell myeloma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; SCT, stem cell transplant; CNS, central nervous system.